Lantheus (NASDAQ:LNTH) Price Target Raised to $85.00 at Mizuho

Lantheus (NASDAQ:LNTH) had its price objective increased by Mizuho from $72.00 to $85.00 in a research note published on Friday morning,Benzinga reports. Mizuho currently has an outperform rating on the medical equipment provider’s stock.

Several other research analysts also recently weighed in on the stock. Citigroup restated an “outperform” rating on shares of Lantheus in a research report on Tuesday. William Blair upgraded Lantheus from a “market perform” rating to an “outperform” rating in a research note on Thursday. Weiss Ratings upgraded Lantheus from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Tuesday, January 6th. Truist Financial lifted their price target on Lantheus from $80.00 to $82.00 and gave the stock a “buy” rating in a research note on Thursday, December 18th. Finally, JonesTrading downgraded Lantheus from a “buy” rating to a “hold” rating in a research note on Friday. Seven equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $82.17.

Lantheus Stock Performance

NASDAQ LNTH traded down $0.52 during mid-day trading on Friday, reaching $74.91. 1,380,211 shares of the stock were exchanged, compared to its average volume of 837,925. The company has a market capitalization of $4.97 billion, a P/E ratio of 22.23 and a beta of -0.08. The company has a debt-to-equity ratio of 0.51, a quick ratio of 2.49 and a current ratio of 2.67. The business’s 50 day moving average is $68.15 and its 200-day moving average is $60.14. Lantheus has a 1 year low of $47.25 and a 1 year high of $111.29.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings data on Thursday, February 26th. The medical equipment provider reported $1.67 earnings per share for the quarter, beating analysts’ consensus estimates of $1.17 by $0.50. The company had revenue of $406.79 million during the quarter, compared to analysts’ expectations of $367.03 million. Lantheus had a net margin of 15.15% and a return on equity of 30.37%. The firm’s revenue for the quarter was up 4.0% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.59 earnings per share. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. On average, equities research analysts forecast that Lantheus will post 6.01 EPS for the current fiscal year.

Institutional Investors Weigh In On Lantheus

A number of institutional investors have recently modified their holdings of LNTH. Hantz Financial Services Inc. lifted its stake in Lantheus by 412.5% during the 3rd quarter. Hantz Financial Services Inc. now owns 492 shares of the medical equipment provider’s stock worth $25,000 after acquiring an additional 396 shares in the last quarter. Elevation Point Wealth Partners LLC acquired a new position in Lantheus in the 2nd quarter valued at about $26,000. First Horizon Corp purchased a new stake in Lantheus during the third quarter worth about $26,000. Smartleaf Asset Management LLC lifted its position in shares of Lantheus by 63.3% during the fourth quarter. Smartleaf Asset Management LLC now owns 508 shares of the medical equipment provider’s stock worth $34,000 after purchasing an additional 197 shares in the last quarter. Finally, Parallel Advisors LLC boosted its stake in shares of Lantheus by 122.6% in the fourth quarter. Parallel Advisors LLC now owns 541 shares of the medical equipment provider’s stock valued at $36,000 after purchasing an additional 298 shares during the period. 99.06% of the stock is owned by institutional investors and hedge funds.

Key Lantheus News

Here are the key news stories impacting Lantheus this week:

• Positive Sentiment: Q4 results: Lantheus reported $1.67 EPS vs. $1.17 expected and revenue of $406.8M vs. $367.0M expected (revenue +4% y/y), showing operational strength and margin improvement. MarketBeat Earnings Report
• Positive Sentiment: Mizuho raised its price target to $85 and set an “outperform” rating, signaling increased analyst conviction and implied upside from current levels. Benzinga
• Positive Sentiment: William Blair upgraded Lantheus from “market perform” to “outperform,” adding another positive analyst endorsement. Street Insider
• Positive Sentiment: Citizens Jmp raised its price target to $78, a modest endorsement that supports the view of upside among some sell‑side analysts. American Banking News
• Neutral Sentiment: JonesTrading reaffirmed a “hold” rating on LNTH, reflecting mixed views on near‑term catalysts. TickerReport
• Neutral Sentiment: Investor materials and transcripts are available (earnings call transcript and presentation), useful for digging into product trends, margin drivers and pipeline commentary. Yahoo Finance Transcript Seeking Alpha Deck
• Negative Sentiment: FY2026 guidance was mixed: EPS guidance of $5.00–$5.25 is roughly in line with consensus (5.16), but revenue guidance of $1.4B–$1.5B leaves room for a slight top‑line miss vs. expectations — a conservative revenue range that could weigh on near‑term sentiment. GlobeNewswire Press Release

About Lantheus

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.